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Abstract
Background: Gastrointestinal diseases are prevalent in dogs, and probiotics could
provide safe alternatives to conventional treatments.
Objective: To evaluate the clinical effects of probiotics when used in the prevention
or treatment of gastrointestinal disease in dogs compared with no treatment, only
symptomatic treatment, or conventional treatment.
Methods: A systematic review was preformed searching AGRICOLA, AGRIS, CAB
Abstracts, Embase, Ovid MEDLINE, and Web of Science to identify articles published
before April 1, 2017. Selection criteria were original research report, those published
in peer reviewed journal, and study investigating in vivo use of probiotic for preven-
tion or treatment of gastrointestinal disease in dogs. Studies were rated based on the
level of evidence, and methodological quality was evaluated by the following vari-
ables: similarities between groups at baseline, risk of bias, and study group size.
Results: One hundred sixty-five studies were identified, of which 17 met the inclusion
criteria—12 concerned acute gastrointestinal disease and 5 concerned chronic gastroin-
testinal disease. The level of evidence ranged between randomized controlled studies
and crossover uncontrolled trials; estimated risk of bias was generally moderate to high;
and sample sizes were small. Feces consistency was the most frequently evaluated clini-
cal variable.
Conclusions and Clinical Importance: The current data point toward a very limited and
possibly clinically unimportant effect for prevention or treatment of acute gastrointesti-
nal disease. For chronic gastrointestinal disease, dietary intervention remains the major
key in treatment, whereas probiotic supplement seems not to add significant improve-
ment. However, studies were often underpowered, underscoring the need for future
larger, preferably multicenter studies.
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Abbreviations: CCECAI, canine chronic enteropathy clinical activity index; cfu, colony forming unit; CIBDAI, canine inflammatory bowel disease activity index; EFSA, European Food Safety
Authority; FS, fecal score; IBD, inflammatory bowel disease; LOE, level of evidence; RCT's, randomized controlled trials.
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1 | INTRODUCTION
Gastrointestinal diseases are common in dogs1,2 and a high percent-
age of dogs presenting with diarrhea receive probiotics as the only or
as a supplemental treatment.3 In addition, probiotics have received
increasing scientific attention over the last decade.
The original observation of a possible positive role played by
selected bacteria is attributed to Elie Metchnikoff, the Russian born
Nobel Prize recipient. He suggested that “The dependence of the
intestinal microbes on the food makes it possible to adopt measures
to modify the flora in our bodies and to replace the harmful microbes
by useful microbes.”4 Probiotics are defined as “live microorganisms
that, when administered in adequate amounts, confer a health benefit
on the host.”5,6 Probiotics can contain either a single strain or a com-
bination of strains and might be combined with a prebiotic.
Prebiotics are defined as “a non-digestible food ingredient that ben-
eficially affects the host by selectively stimulating the growth and/or
activity of 1 or a limited number of bacteria in the colon.”7 Products
containing both probiotic and prebiotic are termed synbiotic. Probiotics
have primarily been used in human medicine in the treatment of gastro-
intestinal diseases.6,8 Based on several systematic reviews and meta-
analyses in human research, there is mounting evidence for a positive
effect of probiotics in patients with antibiotic-associated-diarrhea,9-17
irritable bowel syndrome,15,18-22 and necrotizing enterocolitis.23-27
In humanmedicine, species and strains of the genus Lactobacillus and
Bifidobacterium are the most commonly used probiotics, but strains
belonging to the genus Streptococcus, Bacillus, Propionibacterium,
Escherichia, and Enterococcus as well as the yeast Saccharomyces are
also used as probiotics.9-27 To date, the European Food Safety Authority
(EFSA) has examined 6 bacterial strains (Enterococcus faecium NCIMB
10415 (4b1705), E. faecium NCIMB 10415 (4b1707), Lactobacillus aci-
dophilus DSM 13241 25, Bifidobacterium sp. Animalis, Bacillus subtilis
C3102 (4b1820), and L. acidophilus D2/CSL (4b1715)) for their safety
and efficacy as probiotics or feed additives in dogs.28-30 Currently, the
2 E. faecium strains and the B. subtilis strain are approved for use as feed
additives in dogs.31 Recently, L. acidophilus D2/CSL (4b1715) has also
been evaluated to be safe for use in dogs and cats, with a potential to
reduce the moisture of feces of dogs and cats receiving the additive at
5 × 109 colony forming unit (cfu)/kg feed according to EFSA.30 The
objective of the current systematic review was to evaluate the evidence
concerning the clinical effects (development of vomitus or diarrhea,
duration of diarrhea, feces consistency, defecation frequency, hospitali-
zation duration, or case fatality) of probiotics when implemented in the
prevention or treatment of gastrointestinal disease in dogs.
2 | METHODS
The reporting in this systematic review was according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.32 However, summary and synthesis for the meta-analysis
data as well as additional analysis were not performed because of
the low number of studies and large variations in probiotic strains
investigated as well as reported outcomes. Methods of the analysis
and inclusion criteria were specified in advance and documented in a
protocol (dated March 20, 2017, not published, but available on
request) before data extraction. The detailed protocol was developed
and approved in relation to the initiation of a postgraduate master's
thesis project finalizing the Master of Companion Animal Sciences
specialization in Internal Medicine, University of Copenhagen, Den-
mark. The PICO method was used to formulate the research questions
and guide the search strategy.32 The research question was: “What is
the evidence concerning clinical effects (propensity to develop diar-
rhea under stressful conditions, daily defecation frequency, stool con-
sistency, duration of vomiting or diarrhea, hospitalization length and
case fatality) of probiotics, when implemented in the prevention or
treatment of signs of gastrointestinal disease in dogs?”
2.1 | Eligibility criteria
2.1.1 | Types of studies
Randomized clinical trials, cohort studies, and case reports published
in peer-reviewed journals studying the use of probiotics for preven-
tion or treatment of signs of gastrointestinal disease in dogs were
used. If the abstract was in English, no language restriction was made
and no publication date restriction was made.
2.1.2 | Types of participants
Dogs of any age, at risk of developing signs of gastrointestinal disease
because of stress or parasitism or that had been diagnosed with any
acute or chronic gastrointestinal disease, were selected. Both studies
on kennel dogs and privately owned dogs were considered.
2.1.3 | Types of intervention
Trials comparing the clinical effects of in vivo use of probiotics or syn-
biotics as the only or as a supplemental intervention in the prevention
or treatment of signs of gastrointestinal disease in dogs were consid-
ered. All probiotic species and strains as well as all probiotic doses
were considered. No discrimination was made between vehicle(s)
used in different studies included in the analysis.
2.1.4 | Types of comparison/control
Dogs with similar health/disease status not treated with probiotics or
synbiotics were used as controls.
2.1.5 | Types of outcome
Primary outcome measures were the clinical effect of probiotics on
signs of gastrointestinal disease evaluated by the following variables:
attitude/activity, appetite, vomiting frequency, feces consistency, daily
defecation frequency, weight change, hospitalization duration, case
fatality, as well as number of dogs developing diarrhea because of
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stress or parasitism. In addition, clinical indices of severity of canine
chronic gastroenteritis such as the canine inflammatory bowel disease
(IBD) activity index (CIBDAI)33 and the canine chronic enteropathy clin-
ical activity index (CCECAI)34 were included.
2.2 | Information sources
Studies were identified by searching electronic databases from March
22 to April 1, 2017. This search was applied to Agricola (1970-pre-
sent), Agris (1975-present), CAB Abstracts (1910-present), Embase
(1974-present), MEDLINE (1946-present), and Web of Science
(1945-present). No limits were applied to publication year or lan-
guage, other than a requirement that the abstract should be in
English.
2.3 | Search
We used the following search terms to search the electronic databases:
Dog*; canine; gastro*; intestinal*; enteritis; hemorrhagic gastroen*;
inflammatory bowel disease; IBD; Inflammatory bowel syndrome; IBS;
dysbios*; small intestinal bacterial overgrowth; SIBO; protein losing
enteropat*; PLE; helicobact*; colitis; parasite*; giardia*; viral; virus;
probiotic*; synbiotic*; lactobacill*; bifidobacter*; eschericia; coli;
saccharomyc*; yeast; fung*; streptococc*; bacill*; proprionibact*;
VSL*. Web of Science was searched separately using the search
terms: dog*; canine; probiotic* and synbiotic*.
Search strategy: MEDLINE (OVID)
1. dog*
2. canine
3. 1 or 2
4. gastro*
5. intestinal*
6. enteritis
7. hemorrhagic gastroen*
8. inflammatory bowel disease
9. IBD
10. inflammatory bowel syndrome
11. IBS
12. dysbios*
13. small intestinal bacterial overgrowth
14. SIBO
15. Protein losing enteropat*
16. PLE
17. helicobact*
18. colitis
19. parasite*
20. giardia*
21. viral*
22. virus*
23. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or
16 or 17 or 18 or 19 or 20 or 21 or 22
24. 3 and 23
25. probiotic*
26. symbiotic*
27. 25 or 26
28. 3 and 23 and 27
29. lactobacill*
30. bifidobacter*
31. escherichia
32. coli
33. saccharomyc*
34. yeast
35. fung*
36. streptococc*
37. bacill*
38. proprionibact*
39. VSL*
40. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41. 3 and 23 and 27 and 40
2.4 | Study selection
Eligibility assessment was performed by 1 author (A.P.J.) based on
titles and abstracts in an unblinded standardized manner. By manually
screening references of retrieved papers as well as papers reviewing
the use of probiotics in dogs from 2010 and onward, eligible studies
missed by the electronic search was identified. Subsequently, dupli-
cates were manually removed. Studies fulfilling the inclusion criteria
and those in which fulfillment of the criteria could not be determined
from the abstract were retrieved as full texts. Papers in languages
other than English were translated into Danish using Google Trans-
late. If in doubt of eligibility, the abstract/paper was discussed with
the coauthor (C.R.B.) and disagreements between reviewers were
resolved by consensus.
2.5 | Data collection process
Based on the Cochrane Consumers and Communication Review
Groups's data extraction template,35 a data extraction sheet was
developed. Ten randomly selected studies covering different study
designs were used to test the developed sheet and make final adjust-
ments. Because treatment and prognosis of acute and chronic gastro-
intestinal disease differ, studies were categorized to be either acute or
chronic gastrointestinal disease. One reviewer (A.P.J.) extracted the data
from included studies and the second author checked the extracted data.
Disagreement was resolved by discussion between the 2 authors, lead-
ing to a consensus between the 2.
2.6 | Data Item
Information was extracted from each included trial on (1) the charac-
teristics of dog populations (including whether they were kennel dogs
or privately owned dogs, age, breed, indication for testing probiotic,
and diagnosis); (2) the type of intervention (including type, dose, dura-
tion, and frequency of the probiotic; versus placebo or symptomatic
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or other treatment); and (3) the type of clinical outcome measures
(including the dogs attitude/level of activity, appetite, presence of
vomiting, fecal consistency, presence of blood or mucus in the feces,
defecation frequency, and weight loss). For dogs diagnosed with
chronic gastrointestinal disease, clinical scoring indices (CIBDAI and
CCECAI) were included, with the latter adding serum albumin levels,
presence of ascites/peripheral edema, and owners' subjective assess-
ment of pruritus to the above-mentioned clinical criteria.
2.7 | Risk of bias in individual studies
To ascertain the validity of eligible studies, both authors assessed
all included trials independently. To obtain enough studies for the
review, it was decided to include not only randomized studies, but
also cohort and case-control studies as well as case series. To deter-
mine the strengths of the individual study designs of each study, eligi-
ble studies were graded for level of evidence (LOE) on a scale of I to
IV and with a subclassification of LOE II to 1, 2, and 3 according to
the pyramid of evidence described by Harris and Turner.36 Studies
categorized as LOE I included evidence obtained from a systematic
review (or meta-analysis) of all relevant randomized controlled trials
(RCTs). Studies categorized as LOE II included evidence obtained from
at least 1 randomized controlled trial. Studies categorized as LOE III
included (1) evidence obtained from pseudo-RCT (alternate allocation
or some other method); (2) evidence obtained from comparative stud-
ies (including systematic reviews of such studies) with concurrent con-
trols and allocation not randomized, cohort studies, case control
studies, or interrupted time series with a control group; and (3) evi-
dence obtained from comparative studies with historical controls, 2 or
more single-arm studies or interrupted time series without a parallel
control group. Finally, studies categorized as LOE IV included evi-
dence obtained from case series, either post-test or pretest/post-test,
and represented the lowest LOE.36 The methodological qualities of
the studies were individually evaluated by both authors, for the fol-
lowing 3 measures: similarities among groups at baseline, risk of bias,
and size of study groups. Characterization of similarities between
groups at baseline was evaluated to be good, fair, or poor based on
the following criteria. It was considered good when the health/disease
status of included animals in each group was evaluated and presented
along with information on age, sex, and breed. Evaluation of health/
disease status should include individual clinical examination of study
subjects and a relevant thorough diagnostic workup (CBC and bio-
chemistry, fecal examination, evaluation of severity of gastrointestinal
signs, and, if indicated, characterization of disease severity by endos-
copy). It was considered fair when the health/disease status of
included animals in each group was assessed based on a clinical exam-
ination and evaluation of severity of signs of gastrointestinal disease
and presented along with information on age, sex, and breed. It was
considered poor when important information such as severity of signs
of gastrointestinal disease, age, breed, or sex was lacking for each
group. Risk of bias was evaluated using the Cochrane collaboration's
tool for assessing risk of bias.37 The studies were categorized as hav-
ing high, moderate (unclear), or low risk of selection, performance,
detection, attrition, reporting, and other bias. Finally, the overall com-
bined risk of bias was defined using a predefined numerical system used
in previous veterinary systematic reviews (Table S1A and S1B).38-40
Sample size depends on the outcome variable, its prevalence, and the
expected effect size between study groups. For a general assessment
of the study size, groups were defined as good, moderate, small, and
very small according to the criteria used in previous veterinary system-
atic reviews: >50 (good), 20-49 (moderate), 10-19 (small), and <10 (very
small) animals per group.38-40 If authors had conducted sample size
calculations for specific variables, those calculations were included in
the analysis. Furthermore, because results regarding clinical signs over
a given study period often include repeated measures, it was evalu-
ated whether adequate statistical analysis of repeated measures (eg,
repeated measures analysis of variance or Friedmans test) was appro-
priately applied.
2.8 | Summary measures, synthesis of results, risk of
bias across studies, and additional analyses
The primary outcome measure was the difference in severity of clini-
cal signs of gastrointestinal disease between trial groups (number of
feces samples with unacceptable consistency, defecation frequency,
and CIBDAI of CCECAI). The evidence for or against efficacy of probi-
otic treatment on signs of acute or chronic gastrointestinal disease was
graded as good, fair, or insufficient, according to the following criteria
modified from Summers et al.39 Evidence was graded according to mul-
tiple (good), at least 1 (fair), or no (insufficient) RCT's with a low or low-
to-moderate estimated overall risk of bias. Evidence was also consid-
ered insufficient if (1) interpretation of results was hampered by low
power of the studies or (2) results of outcome measures were con-
flicting. Evidence (good or fair) was considered to support probiotic
treatment if efficacy was demonstrated. Alternatively, evidence (good
or fair) was considered advising against probiotic treatment if lack of
efficacy or adverse effects was demonstrated. Because of the hetero-
geneity in study designs, study populations, probiotic strains, and indi-
cations for intervention among the identified trials, calculations of
relative risks or other statistical combinations of trials were not per-
formed. Risks of bias across studies were evaluated based on a synthe-
sis of the evaluation of the methodological quality of the individual
studies, and additional analyses were not included.
2.9 | Ethical consideration
In 13 of the 17 included studies, study protocols were documented to
have been approved by an ethical committee.
3 | RESULTS
3.1 | Study selection
After the literature search and selection according to the PRISMA
flow diagram (Figure 1), 17 papers were included for further review:
12 studies related to the prevention or treatment of acute
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gastrointestinal disease (acute) and 5 studies concerned prevention or
treatment of chronic gastrointestinal disease (chronic) (Tables 1 and 2).
3.2 | Study characteristics
Published studies investigating in vivo use of probiotics in prevention
or treatment of gastrointestinal disease in dog were found to be
sparse. Only 17 studies fulfilled inclusion criteria for the current sys-
tematic review.
Of the 17 studies included,41-57 7 (5 acute41-45 and 2
chronic53,54) were categorized as RCTs. 1 (acute46) was categorized
as LOE-III-1, pseudo-RCT because of the allocation by alternation,
7 (6 acute47-52 and 1 chronic55) were classified as controlled clinical tri-
als, 4 (3 acute49,51,52 and 1 chronic55) of these claimed to be random-
ized, but randomization was not described, and finally, 2 (chronic56,57)
were crossover uncontrolled trials (Tables 1 and 2).
The included studies involved study groups ranging between
6 and 399 dogs (Tables 1 and 2). For studies investigating prevention
or treatment of signs of acute gastrointestinal disease, study partici-
pants were healthy racing sled dogs,43 healthy dogs undergoing
kenneling stress,45,50,51 dogs with subclinical giardiasis,41 dogs with
lincomycin-induced diarrhea,48 puppies diagnosed with hemorrhagic
gastroenteritis,46 adult dogs diagnosed with acute or intermittent
gastroenteritis,42,44,47,49 and dogs diagnosed with parvovirus diarrhea52
(Table 1). For prevention or treatment of signs of chronic gastrointesti-
nal disease, study participants were pet dogs diagnosed with idiopathic
inflammatory bowel disease,53 dogs with nonspecific dietary sensitiv-
ity57 or food responsive diarrhea,54,55 and dogs with tylosin-responsive
diarrhea56 (Table 2).
Specification of bacterial species included in the probiotic was
missing in 1 of the 17 studies included,47 whereas specification of
bacterial strain(s) used was provided in 11 of 17 included studies.
Only 1 probiotic species was used in 10 of the studies: 4 studies used
E. faecium,41,45,50,53 2 studies used L. acidophilus,46,57 2 studies used
Bifidobacterium animalis,49,51 1 study used Lactobacillus rhamnosus,56
and 1 study used Saccharomyces boulardii.48 The remaining 6 studies
in which information about bacterial species tested was provided used
a combination of 2 or more probiotic species.42-44,52,53,55 The daily
dose of probiotic was mentioned in 15/17 studies. Twelve of these
used doses between 108 and 1010 cfu/d.41-45,49-56 One study tested
different doses of probiotic52 (Table 1).
The most widely used primary outcome measure was fecal con-
sistency/fecal score (FS). Comparison of FS between studies was
hampered by application of different fecal scoring systems, and the
definition of abnormal versus normal feces consistency varied among
studies. For some studies, no specification of abnormal versus normal
fecal consistency was made. In some studies, mean fecal consistency
score was reported over time as repeated measures, whereas other
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studies reported days/time to first normal feces, number of days or
percentage of dogs with diarrhea, or number of days to relapse of
diarrhea. Four studies used clinical scoring as the primary outcome
(Tables 1 and 2).
Secondary outcome measures included defecation frequency, clinical
improvement, appetite evaluation, frequency of vomiting, weight loss, hos-
pitalization duration, and case fatality. Often these variables were reported
to be evaluated, but resultswere seldompresented (Tables 1 and 2).
3.3 | Risk of bias within studies
A summary of “risk of bias” for each study is listed in Tables 1 and 2 and
Table S1A and S1B. More recent studies were more likely to be catego-
rized as having a low/moderate estimated risk of bias. For studies con-
cerning prevention or treatment of signs of acute gastrointestinal disease,
the estimated risk of bias was categorized as low for 2 studies,42,45
low/moderate for 5 studies,41,43,44,49,50 moderate for 1 study,46 and
moderate/high for 4 studies.47,48,51,52 Study group size was very small
(<10 dogs per group) in 4 studies,43,47,48,52 small in 4 studies,41,42,44,49
moderate in 2 studies,45,51 and good in 2 studies.45,50 Similarity at base-
line was poorly characterized in 11 studies,41,43-52 and a fair characteriza-
tion was found in 1 study.42 For studies concerning prevention or
treatment of signs of chronic gastrointestinal disease, the estimated
risk of bias was categorized as low for 1 study,54 low/moderate for
2 studies,53,55 moderate for 1 study,57 and moderate/high for 1 study.56
Study group size was very small (<10 dogs per group) in 3 studies54,56,57
and small (10 < n < 20dogs per group) in 2 studies.53,55 Similarity at base-
line was poorly characterized in 3 studies,54-56 a fair57 characterization
was found in 1 study, and in 1 study it was well characterized.53 Sample
size evaluation was done by power calculation in 1 RCT concerning clini-
cal severity assessed by CCECAI54 and 1 controlled trial, evaluating if pro-
biotic could affect the risk of experiencing at least 1 episode of diarrhea in
dogs diagnosed with nonspecific food sensitivity.45 In the study using the
CCECAI, calculation was based on a type I error of 0.05 and a type II error
of 0.1, which corresponds to a power of 90%. The necessary number of
animals in each group (treatment versus placebo) was estimated to be
n = 11. In the study using the criteria of at least 1 episode of diarrhea in
relation to prevention of kenneling diarrhea, power calculation estimated
the sample size needed to be 582 dogs (Table S1A and S1B). Calculations
were based on a change in incidence of diarrhea from 30% for the
placebo-treated dogs to 20% for the probiotic-treated dogs with a signifi-
cance level of .05 and power of 80%. In comparison, none of the studies
on signs of chronic gastrointestinal disease had sample sizes ≥11. Eight
studies on signs of acute gastrointestinal disease had sample size ≥11
and only 1 had sample size ≥58245 (Table S1B). The dropout rate varied
between 0 and 33% for studies on signs of acute gastrointestinal disease
and 0 and 73% for signs of chronic gastrointestinal disease. One study
did not include statistical analyses.47 Statistical analyses accounted for
repeated measures in 5 studies,41,44,48,52,54 1 study included dog as a
random effect to account for repeated measures,53 whereas the rest of
the studies converted FSs into categories such as number of days with
diarrhea, number of days to last abnormal feces without taking the effect
of the individual dog into account in the statistical analysis.T
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3.4 | Results of individual studies and synthesis of
results
For an overview of results of individual studies, please refer to Tables 1
and 2 and Table S1A and S1B. For studies evaluating effect on preven-
tion of kenneling diarrhea, 1 study found no difference in number of
dogs having ≥1 or ≥2 episodes of diarrhea,50 1 study found a small but
significant improvement in FS during week 3 of kenneling,51 and
1 study, representing the largest number of participants, found a slight
reduction in mean percentage of days scored as diarrhea and number
of dogs experiencing ≥1 or ≥2 days of diarrhea with probiotic treat-
ment.45 For studies evaluating the effect of probiotic in dogs with acute
gastrointestinal disease (acute or intermittent hemorrhagic gastroenter-
itis including parvovirus diarrhea), 1 study did not make a statistical
evaluation,47 1 study found that probiotic treatment reduced the num-
ber of days to resolution of diarrhea,49 while 1 study found a slight
reduction in number of days to last abnormal feces, but no difference
in days to last abnormal feces or vomiting, number of days to first nor-
mal feces or duration of vomiting.49 One study found a significant dif-
ference in change in mean feces consistency on day 7 and on average
throughout the study period in favor of probiotics, but not on days 1-6
or 28 of the study.44 One study used a clinical scoring system evaluat-
ing body temperature, degree of dehydration, heart and respiratory
rates, capillary refill time, colors of the mucosal membranes, sizes of the
submandibular lymph nodes, appetite, frequency of vomiting, diarrhea,
dullness, and fecal consistency.52 The clinical score was significantly
improved in favor of the group treated with probiotic on days 3 and
5 after start of treatment (Table 1). A significant difference in days of
diarrhea in favor of probiotic was found in healthy sled dogs,43 but
this finding might have been confounded by a contagious outbreak in
the kennel, probiotic significantly reduced duration of diarrhea in
lincomycin-induced diarrhea,48 whereas no effect was observed in
chronically Giardia sp. infected dogs,41 both groups remained subclini-
cal. Regarding the studies on treatment of dogs with chronic diarrhea,
there was an overall improvement over time for trial subjects, but no
additional effect of probiotic treatment was identified based on
CECCAI54 and CIBDAI scoring53,55 or time to relapse of diarrhea.56
One study found a significant improvement in FS and defecation fre-
quency in dogs with nonspecific dietary sensitivity after 12 weeks of
probiotic supplementation compared to a prior 12 week feeding with
only a control diet.57 However, there was no difference between
scores and defecation frequency when comparing the probiotic period
with the 4 week period after the probiotic period, where dogs were
only controlled feed.57
Other clinical variables evaluated separately were feces frequency,
vomiting, appetite, weight loss, hospitalization deration, and case
fatality (Table S2). Vomiting was evaluated in 1 study,42 with no statis-
tically significant difference observed between study groups. One
study reported a significant improvement in appetite and a decreasing
frequency of vomiting, when evaluated together.53 This study also
evaluated weight loss, and found weight loss to be less for the
probiotic-treated group. This difference was statistically significant
after 7 days of treatment, but not at the follow-up visit 28 days after
treatment. Two studies evaluated case fatality.46,52 Both studies eval-
uated treatment for parvovirus related gastrointestinal clinical signs.
Both studies found no significant difference in mortality between
treatment groups. One study evaluated hospitalization and found no
significant difference with probiotic treatment.46
Only 1 study in this analysis compared different probiotic
dosages,51 but still the difference in dosages were relatively narrow
107, 108, and 109 cfu/d. In this study, evaluating prevention of signs of
stress-related diarrhea during relocation, an overall statistically signifi-
cant difference in favor of probiotic was seen for mean FS and for fre-
quency of abnormal feces during the first 3 weeks after relocation, but
no difference was observed between probiotic dosages. Only when
weeks were evaluated separately, dogs supplemented with 108 and
109 cfu/d had significantly fewer abnormal feces during the first week
after relocation. Furthermore, even though the difference in FSs
between control group and treatment groups were statistically signifi-
cant, the clinical relevance is questionable. FS was evaluated on a scale
from 1 to 5 of which 1 was categorized as liquid and 5 as extremely dry.
In the control group, FS was estimated to 3.75 ± 0.04 compared to
3.87 ± 0.05 for 107 cfu/d, 3.91 ± 0.05 for 108 cfu/d and 3.94 ± 0.05
for 109 cfu/d.
3.5 | Risk of bias across studies
When assessing the risk of bias that could affect the cumulative evi-
dence, selective reporting bias was an issue for several studies, espe-
cially relating to acute gastrointestinal disease. Four studies on acute
gastrointestinal disease41,43,45,49 and 4 studies on chronic gastroin-
testinal disease53-55,57 were assessed to have low risk of selection
bias; 3 studies on acute gastrointestinal disease42,46,47 and 1 study
on chronic gastrointestinal disease56 were assessed to have moder-
ate risk of selection bias whereas 4 studies on acute gastrointestinal
disease44,48,50,51 were assessed to have high risk of bias (Table S1A
and S1B). Poor characterization of study participants and lacking
information about dropouts were the main causes for being evalu-
ated to be at risk of bias. Furthermore, 12 of the studies reported
industry involvement (Table S1A and S1B); with such a high degree
of industry involvement, there is a risk of publication bias as the
incentive to publish studies showing no effect of probiotics could
be low.
3.6 | Additional analyses
Because of the large heterogeneity in included studies, with regard to
indication, study designs, and choice of probiotic treatment, further
analyses were not performed.
4 | DISCUSSION
4.1 | Summary of evidence
The primary aim of the current systematic review was to identify and
assess the available evidence related to the effect of probiotics in
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preventing or treating signs of gastrointestinal disease in vivo. Overall,
for the prevention or treatment of acute gastrointestinal disease, the
evidence is not sufficiently robust to determine the effectiveness of
probiotics in reducing clinical signs (FS, defecation frequency, and
days with diarrhea). Some studies showed a slightly reduced number
of days with diarrhea or improved FS in relation to kenneling and
acute diarrhea, but the clinical relevance remains questionable. One
study that evaluated prevention of diarrhea in kennel dogs showed an
improvement in feces consistency45 and this study was evaluated to
have a low estimated risk of bias and a high number of dogs in each
group. However, the probiotic product used in that study also con-
tained a prebiotic and the effect proven could therefore not be exclu-
sively linked to the probiotic. Most studies relating to signs of acute
gastrointestinal disease were evaluated to have a moderate to high esti-
mated risk of bias, with a very small or small number of dogs and
poorly reported baseline characteristics of study groups. For the pre-
vention or treatment of clinical signs of chronic gastrointestinal dis-
ease, the evidence was primarily against an effect of probiotic
supplementation on clinical variables and results indicated that die-
tary intervention is more important than probiotic supplementation,
but all of these studies included a very small or small number of
dogs, significantly adversely affecting statistical of power. One of
the studies compared probiotic (VSL#3) as a single treatment with a
combination treatment with prednisone and metronidazole in dogs
with IBD. Both groups improved significantly and the proportion of
dogs achieving remission was similar but it took longer to achieve
remission with probiotics compared with conventional treatment.53
There were no indications that probiotics affected hospitalization or
case fatality in relation to parvovirus diarrhea,46,52 but again because
of the moderate to high estimated risk of bias in these studies, no
conclusion could be made.
4.2 | Limitations
Sample size calculation depends on the initial frequency of dis-
ease/clinical signs and the expected improvement in frequency of a
specific variable after treatment. As mentioned before, abnormal feces
consistency (diarrhea) was the most widely used clinical variable eval-
uated in the included studies. Expected frequency of diarrhea was
higher in studies evaluating treatment of diarrhea compared with
studies evaluating prevention of diarrhea. Considering a type I error
of 0.05 and type II error of 0.2, the sample sizes needed were esti-
mated to be between 11 and 100, with a frequency of diarrhea
decreasing from 100% to between 50 and 90% when probiotics were
used.58 When estimating sample sizes in studies preventing diarrhea,
a significantly higher sample size would be needed than was used in
these studies. Sample sizes needed were estimated to be between
81 and 199 dogs based on the assumptions that frequencies of diar-
rhea were estimated to be present in 20%-40% of the dogs in the
untreated group and that probiotic treatment would decrease this fre-
quency by up to 50%.58
In the 12 studies concerning treatment of diarrhea, sample sizes
were ≥11 in only 5 studies and of these 5 studies, only 1 study had
sample sizes ≥30. A dropout between 14 and 33% of initially included
dogs was seen in 3 of the 5 studies with sample sizes ≥11, including
the study with sample sizes >30. Sample sizes were ≥81 in only 1 of
the 5 studies on preventative effects. Additionally, a reduction in fre-
quency of diarrhea by 50% when implementing probiotics as preven-
tive treatment could be too optimistic. In human studies evaluating
the use of probiotics to reduce diarrhea frequency, a reduction of up
to 25% has most commonly been reported.13,14,16,19,25 It is thus likely
that review conclusions are biased because of the studies being
underpowered.
Effects of probiotics are strain specific, and documented effects of
a product containing probiotics depend on the strain used. In this
study, comparison between studies were difficult considering the
diverse use of probiotic species and for some studies the lack of speci-
fication of strain used. Comparison between studies could be further
confounded considering that the vehicle used for a certain probiotic
product could also influence the probiotic effect.
Considering the optimal dose of probiotics, the official definition
of a probiotic includes the administration of an “adequate amount” in
order to obtain a health benefit. Any further specification of “an ade-
quate” dose has not been made.6,59 The effective dose of probiotic is
influenced by multiple variables, including health endpoint, the spe-
cific probiotic used, delivery vehicle, and route of administration. One
review has examined dose recommendations for probiotics used in
humans.60 The study concluded that no homogeneous picture could
be observed, when dose and efficacy of probiotics were evaluated.
Most studies in humans use doses of 108-1011 cfu/d.9-27 Negative or
positive effects of probiotics outside this relatively narrow dose range
are not available. Products available on the Danish market containing
probiotics recommend the same dose range and most studies in the
current review use doses of 108-1010 cfu/d. The lack of diversity in
doses makes dosage recommendation for canine gastrointestinal dis-
eases impossible.
For all probiotics, it is important for a successful treatment that
there is consistency in regard to label information of the probiotic
strain(s) and the dose included in the probiotic product. Unfortu-
nately, a study that evaluated 25 commercially available products
used for animals in Canada documented poor quality control of pro-
biotic products for the veterinary market.61 Twenty-one of 25 prod-
ucts had label information regarding specific bacterial names.
Information was primarily listed for genus and species, whereas
none of the labels contained information about bacterial strain. Fif-
teen of 25 products had label information regarding viable growth
and only 4 of these 15 products actually had a viable growth equal
to or higher than label information claimed. In the current review,
the included probiotic products could not be tested for consistency
with claim and it is possible that products evaluated did not meet
expected specifications.
Finally, the current review focused on clinical effects of probiotics
and no other possible health effects. To the pet and the caregiver, an
increased defecation frequency is stressful. It increases the need for
walks both day and night as well as risk of fecal soiling indoors. Fur-
thermore, passing of normal feces is often a criterion for discharging a
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dog hospitalized with acute diarrhea. Several studies have investi-
gated other possible health benefits of probiotic treatment. This
includes immune and microbiome modulation as well as possible
modulation of virus or parasite shedding. In 1 study, fecal IgA and
canine distemper virus vaccine-specific circulating IgG and IgA
were higher in the group receiving probiotic (E. faecium).62 In
another study, lymphocyte proliferation and rabies titer were sig-
nificantly higher in sled dogs given probiotic (E. faecium) 4 weeks
after the first vaccination.63 Another study showed an increase in
the T-cell markers: FoxP3+ and TGF-β+ in dogs treated with probi-
otic (VSL#3) as well as what was considered a more balanced effect
on the microbiome compared with conventional treatment for
IBD.53
5 | CONCLUSION
Based on the current review of 17 studies evaluating clinical effect of pro-
biotic supplementation to prevent or treat clinical signs of gastrointestinal
disease, the evidence points toward a limited and possibly clinically
unimportant effect for prevention or treatment of acute gastrointestinal
disease. For chronic gastrointestinal disease, dietary intervention remains
the major key in treatment, whereas probiotic supplement seems not to
add significant improvement. However, this conclusion is based on a lim-
ited number of studies, with a wide methodological diversity, and mainly
low sample sizes. There is a high risk that most of the studies evaluated in
the current review were severely underpowered especially taking into
consideration that baseline characteristics of study groups were generally
very poorly documented.
To achieve better evidence for or against the use of pro-
biotics in gastrointestinal disease in dogs, there is a need for
much larger randomized controlled studies, preferably multicen-
ter, based on rigid protocols focusing on securing and reporting
procedures and baseline characteristics in much more detail for
future evaluations.
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